NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY 2026 and FY 2027 Appropriations for organ donation and transplantation activities (HRSA). FY 2026 and FY 2027 Appropriations for CDC, including the Chronic Kidney Disease Initiative. FY 2026 and FY 2027 Appropriations for kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases. FY 2026 and FY 2027 Appropriations for Dept. of Defense Congressionally Directed Medical Research Program. FY 2026 and FY 2027 Appropriations for Indian Health Service.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN DREW | — |
| TROY ZIMMERMAN | — |
Health Issues HCR
Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Support for xenotransplantation. Comment letter in support for FDA approval of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518). Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN DREW | — |
| MIRIAM ELIZABETH GODWIN | — |
| TROY ZIMMERMAN | — |
Medicare/Medicaid MMM
Initiatives to expand access to home dialysis. Initiatives to expand eligibility and utilization of the Medicare kidney disease education benefit. S.1973 and H.R. 4231, "Treat and Reduce Obesity Act," to provide Medicare coverage of anti-obesity medications and obesity treatment. Support for telemedicine and telehealth access, including the CONNECT for Health Act (S.1261, H.R. 4206) for Medicare beneficiaries. Comments on the Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Comments on Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model. Comments on Organ Procurement Organizations (OPO) Conditions for Coverage Revision. Medicaid eligibility and affordability of coverage under the One Big Beautiful Bill. Activities to address detection and management of chronic kidney disease. Support for Medicare Part D Protected Classes. Implementation of the Advancing American Kidney Health Initiative.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN DREW | — |
| MIRIAM ELIZABETH GODWIN | — |
| TROY ZIMMERMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.